<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610321</url>
  </required_header>
  <id_info>
    <org_study_id>201867</org_study_id>
    <nct_id>NCT03610321</nct_id>
  </id_info>
  <brief_title>Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia</brief_title>
  <official_title>Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyslipidemia is an independent risk factor for cardiovascular events. Statins have become the&#xD;
      cornerstone for the prevention and treatment of atherosclerotic vascular diseases. However,&#xD;
      after the comprehensive control of the traditional risk factors, including unhealthy&#xD;
      lifestyle, hypercholesterolemia, hypertension, hyperglycemia and obesity, there is still a&#xD;
      high risk of residual cardiovascular disease in patients with dyslipidemia. Triglyceride&#xD;
      elevation is the most common type of dyslipidemia and constitutes an important component of&#xD;
      cardiovascular residual risk.&#xD;
&#xD;
      The geraniol has a variety of pharmacological effects, such as anti-inflammatory,&#xD;
      antioxidant, regulating cell apoptosis. Recent studies have confirmed that geraniol plays an&#xD;
      important role in regulating glucose and lipid metabolism, and may have a synergistic role&#xD;
      with statins. Gefarnate Tablets is a kind of anti-ulcer and gastritis treatment. It can&#xD;
      increase the defense ability of gastric mucosa by improving the prostaglandin level and the&#xD;
      concentration of amino hexose in the gastric mucosa. Geraniol is the main components of&#xD;
      Gefarnate Tablets. In the previous study, the investigators found that geraniol induced&#xD;
      autophagy through the SIRT1-AMPK-mTOR pathway and accelerated the degradation of&#xD;
      triglycerides in liver cells, thus reducing the level of triglyceride in the serum of high&#xD;
      fat diet mice. 6 patients with hyperlipidemia were received Gefarnate Tablets (100mg/ times,&#xD;
      3 times per day). A month later, the levels of serum triglyceride, total cholesterol, and low&#xD;
      density lipoprotein cholesterol were decreased significantly. However, the above results need&#xD;
      to be confirmed by the larger clinical research.&#xD;
&#xD;
      Therefore, the aim of this study is to evaluate the effect of Gefarnate Tablets on blood&#xD;
      lipid levels in patients with hypertriglyceridemia and coronary heart disease treated with&#xD;
      statins, provide more options for the treatment of lipid lowering treatment, reduce the risk&#xD;
      of cardiovascular remnant, and improve the long-term prognosis of the coronary heart disease&#xD;
      patients with residual hypertriglyceridemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride change from baseline</measure>
    <time_frame>1 month</time_frame>
    <description>Triglyceride change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol and low density lipoprotein cholesterol changes from baseline</measure>
    <time_frame>1 month</time_frame>
    <description>Total cholesterol and low density lipoprotein cholesterol changes from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Statin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) only for 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefarnate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined treatment with statins (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) and gefarnate (100 mg, three times daily, oral) for 1 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefarnate</intervention_name>
    <description>Gefarnate (100 mg, three times daily, oral) treatment for 1 month.</description>
    <arm_group_label>Gefarnate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.</description>
    <arm_group_label>Gefarnate group</arm_group_label>
    <arm_group_label>Statin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Treatment with statins for more than 1 month&#xD;
&#xD;
          -  Plasma triglyceride level more than 1.7mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atherosclerotic cardiovascular disease (ASCVD) patients with high risk&#xD;
&#xD;
          -  Patients with active liver disease or unexplained elevated levels of aminotransferase&#xD;
&#xD;
          -  Patients with prostatic hypertrophy or those with prostaglandin drugs such as glaucoma&#xD;
&#xD;
          -  Creatinine clearance &lt; 30ml/min&#xD;
&#xD;
          -  an allergy to any component of Gefarnate Tablets or statin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the first affiliated hospital of Harbin medical university</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefarnate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

